Health Technology Kyowa Kirin Co., Ltd. Business Summary
Kyowa Kirin Co., Ltd. engages in the manufacture and sale of medical and pharmaceutical products. It handles the research, development, production, and sale of in vitro diagnostic reagents and ethical drugs concerning renal anemia, leukemia, cancer, allergies, and hypertension. It also produces and sells medical and industrial raw materials such as amino acids, nucleic acid-related compounds, and healthcare products. The company was founded by Benzaburo Kato on July 1, 1949 and is headquartered in Tokyo, Japan.
Financial Highlights
Dec 2021
JPY USD Revenue 352,246M 3,205.93M Gross Profit 253,894M 2,310.79M Operating income 61,110M 556.18M Income before tax 55,475M 504.90M Net income 52,347M 476.43M EBITDA 80,608M 733.64M Diluted EPS 97.38 0.88 Dividends Per Share 46 0.41 Total Assets 921,872M 8,005.48M Total liabilities 184,710M 1,604.01M Total equity 737,162M 6,401.47M Operating cash flow 86,548M 787.70M Currency in JPY Currency in USD
Historical Data Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Revenue
353,380M
271,510M
305,820M
318,352M
352,246M
Gross Profit
215,972M
188,834M
215,129M
227,827M
253,894M
Operating income
62,209M
50,403M
53,354M
55,419M
61,110M
Income before tax
55,849M
66,841M
44,492M
52,263M
55,475M
Net income
42,899M
49,230M
37,674M
47,027M
52,347M
EBITDA
84,241M
66,646M
72,151M
75,885M
80,608M
Diluted EPS
78.30
99.29
43.12
87.49
97.38
Dividends Per Share
27
35
42
44
46
Total Assets
708,295M
741,982M
784,453M
801,290M
921,872M
Total liabilities
92,268M
92,589M
106,203M
102,893M
184,710M
Total equity
616,028M
649,621M
678,250M
698,396M
737,162M
Operating cash flow
64,902M
56,181M
53,655M
39,502M
86,548M
Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Revenue
3,151.41M
2,458.37M
2,805.40M
2,981.70M
3,205.93M
Gross Profit
1,926.02M
1,709.78M
1,973.46M
2,133.84M
2,310.79M
Operating income
554.77M
456.37M
489.43M
519.05M
556.18M
Income before tax
498.05M
605.20M
408.14M
489.49M
504.90M
Net income
382.57M
445.75M
345.59M
440.45M
476.43M
EBITDA
751.25M
603.44M
661.87M
710.74M
733.64M
Diluted EPS
0.69
0.89
0.39
0.81
0.88
Dividends Per Share
0.24
0.31
0.38
0.41
0.41
Total Assets
6,287.57M
6,762.81M
7,218.33M
7,761.05M
8,005.48M
Total liabilities
819.06M
843.90M
977.25M
996.59M
1,604.01M
Total equity
5,468.51M
5,920.98M
6,241.08M
6,764.45M
6,401.47M
Operating cash flow
578.79M
508.68M
492.19M
369.97M
787.70M
Valuation Measures
Dec 2021
PER 32.17 ROA 6.07% ROE 7.29% Operating margin 17.34% Profit margin 14.86%
Key executives
President, CEO & Representative Director:
Masashi Miyamoto
Executive Officer, Manager-Accounting & Finance:
Motohiko Kawaguchi
Executive Officer, GM-Research & Development:
Mitsuo Satoh
Representative Director & Executive Vice President:
Yutaka Osawa
Executive Officer & General Manager-Sales:
Hiroshi Sugitani Shareholders
Kirin Holdings Co., Ltd. (53.4%)
Nomura Asset Management Co., Ltd. (3.5%)
Daiwa Asset Management Co. Ltd. (1.6%)
Nikko Asset Management Co., Ltd. (1.6%)
Massachusetts Financial Services Co. (1.4%)
The Vanguard Group, Inc. (1.1%)
BlackRock Fund Advisors (0.9%)
Mitsubishi UFJ Kokusai Asset Management Co., Ltd. (0.8%)
Norges Bank Investment Management (0.6%)
JPMorgan Asset Management (UK) Ltd. (0.5%)
Contact Details Website: http://www.kyowa-kirin.co.jp Address:
Otemachi Financial City Grand Cube,
1-9-2 Otemachi,
Tokyo,
100-0004,
Japan
Phone:
+81.3.5205.7200
Related Companies
Kyowa Kirin Australia Pty Ltd.
Kyowa Kirin Pharma FZ LLC
Kyowa Kirin Malaysia Sdn. Bhd.
Kyowa Kirin Korea Co., Ltd.
Kyowa Kirin Pharma SRL
Kyowa Kirin Pharma sro
Kyowa Kirin Austria GmbH
Kyowa Kirin SARL
Kyowa Kirin AB
Kyowa Kirin Pharma BV
Kyowa Kirin Holdings BV
Kyowa Kirin Farmaceutica SL
Kyowa Kirin Ireland Ltd.
Kyowa Kirin Canada, Inc.
Kyowa Kirin Frontier Co., Ltd.
Kyowa Medical Promotion Co., Ltd.
Kyowa Kirin GmbH
Strakan International SARL
Kyowa Kirin Plus Co., Ltd.
Kyowa Hakko Bio Co. Ltd. (Beijing)
Kyowa Hakko Bio (Shanghai) Trading Co., Ltd.
Kyowa Hakko Bio (Shanghai) Trading Co. Ltd. /Beijing Branch/
Kyowa Hakko Bio Shanghai Trading Co. Ltd. /Guangzhou/
Kyowa Hakko Kirin (Hong Kong) Co. Ltd.
Kyowa Hakko Kirin (Taiwan) Co. Ltd.
Kyowa Hakko Kirin (Singapore) Pte Ltd.
Kyowa Hakko Kirin China Pharmaceutical Co., Ltd.
Kyowa Hakko Kirin (Thailand) Co. Ltd.
ProStrakan SRL
Kyowa Hakko Kirin America, Inc.
Competitors
Genexine, Inc.
Innate Pharma SA Class A
FibroGen, Inc.
Tonix Pharmaceuticals Holding Corp.
Springworks Therapeutics, Inc.
Tetralogic Pharmaceuticals Corporation
Citius Pharmaceuticals Inc
Ikena Oncology, Inc.
Seagen, Inc.
Heron Therapeutics Inc
Prometheus Biosciences, Inc
Copyright © 2022 FactSet Research Systems Inc. All rights reserved.
Last Updated on 18 May, 2022
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
Celebrate our next chapter
Free access for everyone - Sep. 30
Find out more
By continuing to browse this website, you accept cookies which are used for several reasons such as personalizing content/ads and analyzing how this website is used. Please review our
Cookie Policy
to learn how you can update your cookie settings.
Accept & Continue
Close